One-year incidence of low libido in women using levonorgestrel subdermal implant as contraception. Cohort study. Armenia, Colombia, 2014-2019
- PMID: 33878812
- PMCID: PMC8372765
- DOI: 10.18597/rcog.3520
One-year incidence of low libido in women using levonorgestrel subdermal implant as contraception. Cohort study. Armenia, Colombia, 2014-2019
Abstract
Objective: To determine the incidence of low libido in women using the levonorgestrel (LNG) subdermal implant for contraception after 12 months and to identify other adverse effects. Materials and methods: Cohort study that included women over the age of 18, with no children or prior gestations and in a stable relationship, with an LNG implant inserted at least three months before in a private teaching hospital in Armenia (Quindío), Colombia, between 2014 and 2019. Women with a history of sexual dysfunction, sexually transmitted infections in the past six months, weighing more than 89 kg and difficult to follow were excluded. Consecutive sampling was used. The characteristics of the study population were described, the cumulative incidence of low libido and the adverse effects related to the LNG subdermal implant after 12 months of follow-up were estimated. The tool used was the Female Sexual Dysfunction Index (FSFI). Descriptive statistics were applied. Results: The participants were 238 women with a mean age of 24.69 (SD ± 5.82) years. An 18.82% incidence of low libido was found. In 60.25% of the women were diagnosed with low libido in the first 6 months of follow-up. Adverse effects manifested as early as 3 months after the insertion of the implant, the most frequent being irregular bleeding (62.34%), followed by amenorrhea (38.91%) and weight gain (33.89%). Conclusions: It is important for practitioners and users to become aware of the presence of low libido disorder and the adverse events that may occur with the use of the levonorgestrel subdermal implant. Future research is required to confirm these findings and the underlying physiological cause.
Objetivo: definir la incidencia de deseo sexual hipoactivo (DSH) en mujeres que planifican con el implante subdérmico de levonorgestrel (LNG) después de 12 meses, y conocer otros efectos adversos. Materiales y métodos: estudio de cohorte, cuyas participantes fueron mujeres mayores de 18 años sin hijos ni embarazos previos y con pareja estable, a quienes se les había insertado el implante de LNG al menos tres meses previos en una clínica privada de carácter universitario en Armenia (Quindío), Colombia, entre 2014 y 2019. Se excluyeron mujeres con antecedentes de disfunción sexual, infecciones de transmisión sexual en los últimos 6 meses, peso mayor a 89 Kg y dificultades para el seguimiento. El muestreo fue consecutivo. Se describieron las características de la población estudiada, se estimó la incidencia acumulada de DSH y efectos adversos relacionados con el implante subdérmico de LNG a 12 meses de seguimiento. Se aplicó como instrumento el Índice de Función Sexual Femenino. Se utilizó estadística descriptiva. Resultados: participaron 238 mujeres cuya edad media fue de 24,69 (DE ± 5,82) años. Se determinó una incidencia de deseo sexual hipoactivo del 18,82%. El 60,25% de las mujeres fueron diagnosticadas con DHS en los primeros 6 meses de seguimiento. Los efectos adversos se hicieron presentes desde los primeros 3 meses de la inserción del implante, el sangrado irregular (62,34%) fue el más frecuente, seguido de la amenorrea (38,91%) y el aumento de peso (33,89%). Conclusiones: es importante que los médicos y las usuarias se informen sobre la presencia del trastorno de deseo sexual hipoactivo y los efectos adversos que pueden surgir con el uso del implante subdérmico de levonorgestrel. Las futuras investigaciones deben confirmar estos hallazgos, así como su eventual base fisiológica.
Keywords: contraceptives; physiological sexual dysfunctions; risk factors; women; family planning services; levonorgestrel.
Conflict of interest statement
Similar articles
-
Contraception with two levonorgestrel rod implants. A 5-year study in the United States and Dominican Republic.Contraception. 1998 Nov;58(5):275-82. doi: 10.1016/s0010-7824(98)00112-7. Contraception. 1998. PMID: 9883382 Clinical Trial.
-
A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant.Fertil Steril. 2016 Jul;106(1):151-157.e5. doi: 10.1016/j.fertnstert.2016.02.036. Epub 2016 Mar 24. Fertil Steril. 2016. PMID: 27016644 Clinical Trial.
-
Cervical cytology associated with levonorgestrel contraception.Acta Cytol. 1995 Jan-Feb;39(1):45-9. Acta Cytol. 1995. PMID: 7847008 Clinical Trial.
-
Levonorgestrel subdermal implants. A review of contraceptive efficacy and acceptability.Drugs. 1998 Jun;55(6):861-87. doi: 10.2165/00003495-199855060-00019. Drugs. 1998. PMID: 9617600 Review.
-
Levonorgestrel subdermal implants. Contraception on trial.Drug Saf. 1997 Dec;17(6):360-8. doi: 10.2165/00002018-199717060-00002. Drug Saf. 1997. PMID: 9429835 Review.
References
-
- Espitia-De La Hoz FJ. Prevalence and characterisation of sexual dysfunctions in women, in 12 Colombian cities, 2009-2016. Rev Colomb Obstet Ginec. 2018;69(1):9–21. doi: 10.18597/rcog.3035. - DOI
-
- Hayes RD, Dennerstein L, Bennett CM, Koochaki PE, Leiblum SR, Graziottin A. Relationship between hypoactive sexual desire disorder and aging. Fertil Steril. 2007;87(1):107–112. https://doi.org/10.1016j.fertnstert.2006.05.071 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous